Ascendis Pharma A/S - ADR

NASDAQ:ASND   3:59:50 PM EDT
120.62
+2.43 (+2.06%)
Regulatory, Other Pre-Announcement

Ascendis Pharma A/S Announces Target Enrollment Achieved In The Phase 3 Trial Of Transcon™ Pth (Palopegteriparatide) in Adults with Hypoparathyroidism

Published: 07/06/2021 12:41 GMT
Ascendis Pharma A/S - ADR (ASND) - Ascendis Pharma A/s Announces Target Enrollment Achieved in the Phase 3 Pathway Trial of Transcon™ Pth (palopegteriparatide) in Adults With Hypoparathyroidism (hp) and Provides a Comprehensive Global Clinical Program Update.
Ascendis Pharma A/s - Expects to Complete Enrollment of Subjects Still in Screening Within One Week.